|
About the Confirmatory Testing category -Please read before posting
|
|
1
|
715
|
March 30, 2025
|
|
N-Nitroso Vonoprazan impurity peak area variation observed during drug product analysis by LCMS
|
|
1
|
65
|
June 8, 2026
|
|
MS Method Development Criterias?
|
|
1
|
136
|
June 2, 2026
|
|
EDTA-Related Nitrosamine Impurities: Two Critical Pain Points in Pharma R&D
|
|
5
|
282
|
June 1, 2026
|
|
Understanding In Vitro Nitrosamine Formation During Sample Preparation
|
|
4
|
228
|
June 1, 2026
|
|
Solution stability of NDSRI
|
|
8
|
354
|
May 25, 2026
|
|
Development and Validation of a Trace-Level LC–MS/MS Method for the Determination of N-Nitroso Clozapine in Clozapine Drug Substance -Pub
|
|
0
|
94
|
May 20, 2026
|
|
Strategies for Mitigating In-Source Fragmentation in NDSRI Analysis using LC-MS
|
|
4
|
2823
|
May 20, 2026
|
|
UHPLC-MS/MS Single Run Quantification Method for Simultaneous Determination of Triazolopyrazine and N-Nitroso-Triazolopyrazine in Sitagliptin; Risk Assessment, Scavenger-Based Mitigation, and Stress Stability Study -Pub
|
|
0
|
76
|
May 20, 2026
|
|
Liquid Chromatography–High-Resolution Mass Spectrometric Determination of Nitrite Ion Concentration in the Natural Water Resources -Pub
|
|
0
|
71
|
May 20, 2026
|
|
Simultaneous Determination of Duloxetine and N-Nitroso-Duloxetine in Reactor Cleaning Solvent Samples by LC–HRMS: Formation, Quantitation, and Green -Pub
|
|
0
|
105
|
May 20, 2026
|
|
Nitrosamines: Mass Spectrometry-Based Analytical Procedures Criterias
|
|
10
|
4400
|
May 20, 2026
|
|
N Nitroso Tadalfil
|
|
14
|
977
|
May 20, 2026
|
|
Analytical challenge for determination of instable standard of other N-nitroso structure
|
|
13
|
1020
|
May 18, 2026
|
|
N-Nitroso Metamizole Impurity C
|
|
4
|
358
|
May 13, 2026
|
|
N-Nitroso Desethyl Amiodarone in Amiodarone HCl Tablets by LC-MS/MS Metodu
|
|
2
|
172
|
May 12, 2026
|
|
Diluent Selection for Nitrosamine Impurities
|
|
7
|
308
|
May 8, 2026
|
|
How to overcome blank interference at NDBA
|
|
4
|
183
|
April 27, 2026
|
|
Maximum Daily Dose (MDD) of Cream Formulation
|
|
1
|
192
|
April 17, 2026
|
|
N-Nitroso meglumine
|
|
26
|
2317
|
April 8, 2026
|
|
MDD for cream formulation
|
|
0
|
102
|
April 3, 2026
|
|
N-nitroso-Furosemide
|
|
2
|
537
|
March 31, 2026
|
|
Analysis method of cream
|
|
6
|
277
|
March 30, 2026
|
|
Optimized UHPLC–Derivatization Method for Low-Level Nitrite Detection in Pharmaceutical Excipients-Pub
|
|
0
|
219
|
March 23, 2026
|
|
How to Validate High-Resolution Mass Spectrometry for Nitrosamine Detection in Pharmaceuticals
|
|
3
|
371
|
March 21, 2026
|
|
Minimizing in Source Fragmentation for Mass Spectrometry Based NDSRI Analytical Procedures: A Case Study of Nitroso-bumetanide -Pub
|
|
4
|
332
|
March 19, 2026
|
|
Differences in Physical Form of Nitrosamine Reference Standards: USP vs. Other Suppliers
|
|
2
|
168
|
March 18, 2026
|
|
Scientific Clarification Request on Analytical Approach for Nitrosamine Determination in Quetiapine Oral Suspension
|
|
3
|
246
|
March 17, 2026
|
|
Challenges in developing an analytical method for N‑nitroso‑ambroxol -
|
|
1
|
161
|
March 14, 2026
|
|
Testing of N-nitroso-cinacalcet
|
|
8
|
1067
|
March 14, 2026
|